Clinical Progress Note: Procalcitonin in the Management of Pediatric Lower Respiratory Tract Infection.

TitleClinical Progress Note: Procalcitonin in the Management of Pediatric Lower Respiratory Tract Infection.
Publication TypeJournal Article
Year of Publication2019
AuthorsKatz SE, Sartori LF, Williams DJ
JournalJ Hosp Med
Volume14
Issue11
Pagination688-690
Date Published2019 11 01
ISSN1553-5606
KeywordsAnti-Bacterial Agents, Biomarkers, Child, Humans, Procalcitonin, Respiratory Tract Infections
Abstract

Procalcitonin (PCT) is a biomarker that has shown promise to identify bacterial etiology in acute infections, including bacterial lower respiratory tract infection (LRTI). In 2017, the United States Food and Drug Administration (FDA) approved the use of PCT as a diagnostic aid to guide the decisions around antibiotic therapy in acute LRTI. Although most of the data supporting the use of PCT for LRTI stems from adult studies, the high disease burden, predominance of viral etiologies, and frequent diagnostic uncertainty resulting in antibiotic overuse make pediatric LRTI an ideal target for the use of PCT as a diagnostic aid. This review eval-uates and summarizes the current evidence regarding the role of PCT in the clinical care of pediatric LRTI, including its use in guiding antibiotic use and prognosticating disease severity.

DOI10.12788/jhm.3301
Alternate JournalJ Hosp Med
PubMed ID31532736
PubMed Central IDPMC6827540
Grant ListT32 AI095202 / AI / NIAID NIH HHS / United States